You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Human epidermal growth factor receptor 2 Positive Breast Cancer

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

Not yet recruiting
  • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
  • PERT-IJS plus trastuzumab, carboplatin and docetaxel
  • Perjeta plus trastuzumab, carboplatin and docetaxel
  • (no location specified)
Sep 21, 2023

Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

Active, not recruiting
  • Metastatic Breast Cancer
  • Hospitalet de Llobregat, Barcelona, Spain
  • +6 more
Jan 23, 2023

Unraveling KAdcyla Resistance In Human Epidermal Growth Factor

Completed
  • Advanced Breast Cancer
    • Sevilla, Andalucía, Spain
    • +9 more
    Jan 12, 2023

    Breast Cancer Trial in Shanghai (HS-10352 combined with fulvestrant (Stage 1), HS-10352 combined with fulvestrant (Stage 2))

    Recruiting
    • Breast Cancer
    • HS-10352 combined with fulvestrant (Stage 1)
    • HS-10352 combined with fulvestrant (Stage 2)
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Aug 15, 2022

    Human Epidermal Growth Factor Receptor 2-Positive Unresectable

    Active, not recruiting
    • Metastatic Breast Cancer
    • Locally Advanced Breast Cancer
      • Athens, Greece
      • +1 more
      Jun 20, 2022

      Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in

      Not yet recruiting
      • Anatomic Stage II Breast Cancer AJCC v8
      • +3 more
      • Biospecimen Collection
      • +7 more
      • Portland, Oregon
        SWOG
      Sep 27, 2023

      Breast Cancer, Chemo Effect Trial (Capecitabine)

      Not yet recruiting
      • Breast Cancer
      • Chemotherapy Effect
      • (no location specified)
      Mar 9, 2022

      ER+, HER2-, Metastatic Breast Cancer Trial in China (AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus)

      Recruiting
      • ER+, HER2-, Metastatic Breast Cancer
      • Beijing, China
      • +5 more
      Jan 13, 2023

      Metastatic Breast Cancer Trial in Zhengzhou (Famitinib, SHR6390, Fulvestrant)

      Recruiting
      • Metastatic Breast Cancer
      • Zhengzhou, Henan, China
        Henan Cancer Hospital
      Jan 25, 2022

      Breast Tumors Trial in Shenyang (Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting

      Recruiting
      • Breast Neoplasms
      • Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
      • Shenyang, Liaoning, China
        Shengjing Hospital affiliated to China Medical University
      Jul 30, 2022

      Among Patients Receiving Palbociclib Combinations for Hormone

      Recruiting
      • Breast Neoplasms
      • Palbociclib plus an aromatase inhibitor
      • Palbociclib plus fulvestrant
      • Doha, Qatar
        Hamad Medical Corporation
      Nov 18, 2021

      HER2(Human Epidermal Growth Factor Receptor 2) -Positive

      Not yet recruiting
      • Breast Cancer
        • Arkhangelsk, Russian Federation
        • +27 more
        Jun 13, 2023

        Molecular Imaging in HER2-positive Breast Cancer During

        Enrolling by invitation
        • HER2-positive Breast Cancer
        • Female
        • Tomsk, Russian Federation
        • +1 more
        Jun 7, 2022

        Breast Cancer Trial in Port Saint Lucie (RGT-419B, RGT-419B in combination with hormonal therapy)

        Recruiting
        • Breast Cancer
        • RGT-419B
        • RGT-419B in combination with hormonal therapy
        • Port Saint Lucie, Florida
          Hem-Onc Associates of the Treasure Coast
        Apr 18, 2022

        Breast Cancer, Estrogen Receptor-positive Breast Cancer Trial in Charlottesville (Aspirin, Tamoxifen Pill, Doxorubicin)

        Withdrawn
        • Breast Cancer
        • Estrogen Receptor-positive Breast Cancer
        • Charlottesville, Virginia
          University of Virginia
        Nov 12, 2021

        Breast Cancer Female Trial in Tomsk (99mTc-ADAPT6, 99mTc-DARPinG3)

        Recruiting
        • Breast Cancer Female
        • Tomsk, Russian Federation
          Tomsk NRMC
        May 12, 2022

        HR-positive,HER2-negative in Advanced Breast Cancer Trial in Beijing (TQB3616 capsules, TQB3616-matching , Fluvestrin injection)

        Recruiting
        • HR-positive,HER2-negative in Advanced Breast Cancer
        • TQB3616 capsules
        • +2 more
        • Beijing, Beijing, China
        • +1 more
        May 11, 2022

        Neoadjuvant Therapies for HER2+ Breast Cancer Trial (docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP),

        Not yet recruiting
        • Neoadjuvant Therapies for HER2+ Breast Cancer
        • docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP)
        • docetaxel/trastuzumab/pertuzumab (THP)
        • (no location specified)
        Apr 23, 2021

        Breast Cancer Trial in Paris, Barcelone, Madrid (Trastuzumab and non-pegylated liposomal doxorubicin)

        Completed
        Has Results
        • Breast Cancer
        • Trastuzumab and non-pegylated liposomal doxorubicin
        • Paris, France
        • +3 more
        Feb 8, 2022

        Breast Cancer Trial in Poland, United States (ZN-c5, Abemaciclib)

        Recruiting
        • Breast Cancer
        • Gilbert, Arizona
        • +6 more
        Feb 14, 2022

        A NIS of Alpelisib in Combination With Fulvestrant in

        Not yet recruiting
        • Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
        • Alpelisib
        • Fulvestrant
        • (no location specified)
        Aug 9, 2022

        Breast Cancer Trial in United States (T-DM1)

        Active, not recruiting
        • Breast Cancer
        • Duarte, California
        • +13 more
        Aug 25, 2022

        Breast Cancer Trial in Egypt

        Completed
        • Breast Cancer
          • Alexandria, Egypt
          • +7 more
          Jan 24, 2022

          Breast Cancer, Invasive Breast Cancer Trial in Milwaukee (Anastrozole, Letrozole, Exemestane)

          Active, not recruiting
          • Breast Cancer
          • Invasive Breast Cancer
          • Milwaukee, Wisconsin
            Froedtert Hospital
          Sep 16, 2021

          Breast Cancer Invasive Trial in Shanghai (Pyrotinib, Trastuzumab, Pertuzumab)

          Active, not recruiting
          • Breast Cancer Invasive
          • Shanghai, Shanghai, China
            Ruijin Hospital, Shanghai Jiaotong University School of Medicine
          Mar 28, 2022